通过通过EIF4B/PI3K/AKT途径抑制纤维化进展,CCP1抑制肺纤维化
Qiang Ren1, Yifei Pan2, Zhennan Tian1
1Department of Respiratory Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Cell biology international
|July 1, 2025
概括
细胞质碳素酶1 (CCP1) 通过抑制EIF4B/PI3K/AKT通路来抑制肺纤维化 (PF). 低调CCP1促进纤维化,为这种致命的肺病提供了潜在的治疗标.
科学领域:
- 细胞生物学 细胞生物学
- 分子生物学分子生物学
- 纤维性疾病的发病因子
背景情况:
- 肺纤维化 (PF) 是一种慢性,致命的肺病,病原性机制尚不清楚.
- 异形性肺纤维化 (IPF) 占PF病例的很大一部分,突出了需要机械洞察的需要.
研究的目的:
- 为了确定关键的基因和涉及PF病变发生的途径.
- 阐明细胞质碳素酶1 (CCP1) 在PF发育中的作用.
- 研究CCP1在调节纤维化过程中的作用机制.
主要方法:
- 使用LASSO回归和随机森林分析进行基因表达概况.
- 使用TGFβ1诱导的MRC-5细胞的体外研究和使用白素诱导的PF小鼠模型的体内研究.
- 功能性检测包括qRT-PCR,西部斑,免疫组织化学,RNA干扰和共同免疫沉.
主要成果:
- 细胞质碳素酶1 (CCP1) 在纤维状况下显著下调.
- 抑制CPP1促进了MRC-5细胞迁移,增殖和纤维化表型,而CPP1过度表达抑制了这些过程.
- CCP1通过与真核细胞启动因子4B (EIF4B) 结合来抑制PI3K/AKT信号通路,从而抑制PF的发展.
结论:
- 在肺纤维化的发展中,CCP1起着至关重要的抑制作用.
- CCP1/EIF4B/PI3K/AKT轴代表了一种新的途径,涉及PF的病原性.
- CCP1成为治疗肺纤维化的潜在治疗标.
相关概念视频
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
263
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
263
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
3.1K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
3.1K
01:20COPD: Pathogenesis and Clinical Features
535
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
535
01:24Cystic Fibrosis: Management
228
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
228
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
2.9K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.9K
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
2.9K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.9K